Stockscreener 앱 받기
0.74%
시장 영업 전:
Altimmune Inc 주식(ALT)의 최신 뉴스
Lost Money on Altimmune, Inc. (ALT)? Contact Levi & Korsinsky About Fraud Investigation - ACCESS Newswire
Altimmune Inc. Stock Analysis and ForecastFree High-Return Strategy Alerts - Autocar Professional
Investors in Altimmune, Inc. (ALT) Warned of Potential Securities FraudContact Levi & Korsinsky Today - Newsfile
What drives Altimmune Inc. stock priceHigh-yield trading alerts - Autocar Professional
Is Altimmune Inc. a good long term investmentRapid market gains - jammulinksnews.com
(ALT) Technical Pivots with Risk Controls - news.stocktradersdaily.com
ALT ALERT: Ongoing Investigation Into Altimmune, Inc.Contact Levi & Korsinsky - ACCESS Newswire
Securities Litigation as a Strategic Tool: Lessons from Altimmune's Legal Challenges and the Role of the Schall Law Firm - AInvest
ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm - FinancialContent
What analysts say about Altimmune Inc. stockExceptional earning trajectories - jammulinksnews.com
Did Altimmune, Inc. (ALT) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
Lost Investment in Altimmune, Inc. (ALT)? Levi & Korsinsky Launches Securities Fraud Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc.ALT - WV News
Why Altimmune Inc. stock attracts strong analyst attentionHigh Yield Opportunities - beatles.ru
What makes Altimmune Inc. stock price move sharplyFree Smart Money Stock Analysis - Newser
How Altimmune Inc. stock performs during market volatilityTrending Stock Alert - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - GlobeNewswire Inc.
OneDigital Investment Advisors LLC Sells 2,887 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Concurrent Investment Advisors LLC Purchases New Holdings in Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune (NASDAQ:ALT) Upgraded to “Strong Sell” at The Goldman Sachs Group - Defense World
Altimmune (NASDAQ:ALT) Upgraded at The Goldman Sachs Group - Defense World
Pomerantz LLP investigates securities fraud claims in Altimmune's IMPACT Phase 2b trial. - AInvest
Altimmune (NASDAQ:ALT) Rating Increased to Strong Sell at The Goldman Sachs Group - Defense World
The Goldman Sachs Group Upgrades Altimmune (NASDAQ:ALT) to Strong Sell - Defense World
Altimmune (NASDAQ:ALT) Stock Rating Upgraded by The Goldman Sachs Group - Defense World
JMP Securities Lowers Altimmune (NASDAQ:ALT) Price Target to $15.00 - Defense World
Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment - TipRanks
Altimmune falls after Goldman resumes coverage with "sell", citing competition - TradingView
Citizens JMP lowers Altimmune stock price target to $15 on fibrosis miss - Investing.com Nigeria
Goldman Sachs downgrades Altimmune stock to Sell on pemvidutide concerns - Investing.com Canada
Altimmune Plunges 14.56% on Goldman Sachs Downgrade - AInvest
Altimmune resumed with a Sell at Goldman Sachs - TipRanks
Sell Rating for Altimmune Inc. Due to Financial Struggles and Competitive Challenges in Drug Development - TipRanks
Altimmune enrolls first patient in ALD treatment trial By Investing.com - Investing.com South Africa
ATTENTION Altimmune, Inc. (ALT) Investors: Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
How To Trade (ALT) - news.stocktradersdaily.com
Levi & Korsinsky Launches Fraud Investigation on Behalf of Altimmune, Inc. (ALT) Shareholders - ACCESS Newswire
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluati - GuruFocus
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) - The Manila Times
Altimmune, Inc. Enrolls First Patient in RESTORE Phase 2 Trial for Pemvidutide in Alcohol-Associated Liver Disease - Quiver Quantitative
Altimmune enrolls first patient in ALD treatment trial - Investing.com
Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial - Insider Monkey
ALT ALERT: Levi & Korsinsky Investigates Altimmune, Inc. for Possible Securities Fraud Violations - ACCESS Newswire
0.87%
0.17%
자본화:
|
볼륨(24시간):